Theranostics · 2025 · 15 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyNeoplasiaCancer ImmunotherapyOncogenic Signaling PathwaysReceptor Tyrosine Kinase SignalingTargeted Cancer TherapyLysosomal Cargo DegradationLysosomal Degradation PathwaysTfeb Regulation
: This study identifies, for the first time, GK as a promising TFEB agonist for LUAD treatment. TFEB activation promotes TRIM25-mediated K48-linked polyubiquitination and lysosomal degradation of GPX4, driving ferroptosis. This ferroptosis-driven mechanism offers a novel strategy to enhance ferroptosis-based anti-LUAD therapies.